Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4).

Abstract

GSK2798745, a clinical candidate, was identified as an inhibitor of the transient receptor potential vanilloid 4 (TRPV4) ion channel for the treatment of pulmonary edema associated with congestive heart failure. We discuss the lead optimization of this novel spirocarbamate series and specifically focus on our strategies and solutions for achieving desirable potency, rat pharmacokinetics, and physicochemical properties. We highlight the use of conformational bias to deliver potency and optimization of volume of distribution and unbound clearance to enable desirable in vivo mean residence times.

• Authors: Carl A Brooks, Linda S Barton, David J Behm, Hilary S Eidam, Ryan M Fox, Marlys Hammond, Tram H Hoang, Dennis A Holt, Mark A Hilfiker, Brian G Lawhorn, Jaclyn R Patterson, Patrick Stoy, Theresa J Roethke, Guosen Ye, Steve Zhao, Kevin S Thorneloe, Krista B Goodman, Mui Cheung
• Journal: ACS medicinal chemistry letters (ACS Med Chem Lett) Vol. 10 Issue 8 Pg. 1228-1233 (Aug 08 2019) ISSN: 1948-5875 [Print] United States
• PMID: 31413810 (Publication Type: Journal Article)